Search
Atidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic … a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
Synonyms: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence, Autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) geneSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalthe central nervous system. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Products: Miochol E, MIOCHOL EAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood. … [A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807]
Amylocaine
go.drugbank.com/drugs/DB09088ApprovedWithdrawnElsewhere in English speaking countries it was referred to as Stovaine, given the meaning of the French word 'fourneau' as 'stove' in English [L1882]. … , and prilocaine in the 1940s and 1950s superseded and made the use of amylocaine obsolete.
Products: Dentition Sirop DeConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] One disadvantage of this approach is the possible development of antibodies (inhibitors) towards the administered replacement factor, rendering them less effective and increasing the likelihood
Rocuronium
go.drugbank.com/drugs/DB00728ApprovedInvestigationalIt is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. … [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
Products: BROMURO DE ROCURONIO 50 MG/5ML., BROMURO DE ROCURONIO 25MG/2.5MLPhenolphthalein
go.drugbank.com/drugs/DB04824ApprovedWithdrawnPhenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.
Mixtures: Le 100 BRelebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigational[label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568] … Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam].